Equities Analysts Issue Forecasts for KALV FY2026 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Free Report) - Investment analysts at Cantor Fitzgerald increased their FY2026 earnings per share (EPS) estimates for KalVista Pharmaceuticals in a report released on Monday, July 14th. Cantor Fitzgerald analyst P. Stavropoulos now anticipates that the specialty pharmaceutical company will earn ($2.83) per share for the year, up from their previous forecast of ($2.90). The consensus estimate for KalVista Pharmaceuticals' current full-year earnings is ($3.56) per share.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last released its earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same period last year, the company posted ($1.07) earnings per share.

KALV has been the topic of several other research reports. Jones Trading reiterated a "buy" rating and set a $30.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Leerink Partners upped their target price on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the stock an "outperform" rating in a report on Monday, July 7th. HC Wainwright upped their target price on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the stock a "buy" rating in a report on Tuesday, July 8th. Needham & Company LLC restated a "buy" rating and issued a $28.00 price objective on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. Finally, JMP Securities upped their price objective on KalVista Pharmaceuticals from $19.00 to $27.00 and gave the company a "market outperform" rating in a research note on Tuesday, July 8th. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $26.29.

KalVista Pharmaceuticals Stock Performance

KALV traded down $0.62 on Wednesday, hitting $15.39. 1,279,131 shares of the company were exchanged, compared to its average volume of 588,861. KalVista Pharmaceuticals has a 12 month low of $7.30 and a 12 month high of $16.32. The company has a market cap of $768.79 million, a PE ratio of -4.17 and a beta of -0.04. The stock's fifty day moving average is $12.89 and its 200-day moving average is $11.47.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in KALV. Aquatic Capital Management LLC acquired a new stake in shares of KalVista Pharmaceuticals in the 4th quarter valued at $44,000. Earned Wealth Advisors LLC acquired a new stake in shares of KalVista Pharmaceuticals during the 1st quarter valued at $44,000. GAMMA Investing LLC boosted its holdings in shares of KalVista Pharmaceuticals by 567.3% during the 1st quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock valued at $51,000 after acquiring an additional 3,767 shares in the last quarter. CWM LLC boosted its holdings in shares of KalVista Pharmaceuticals by 12,636.1% during the 1st quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company's stock valued at $53,000 after acquiring an additional 4,549 shares in the last quarter. Finally, Tower Research Capital LLC TRC boosted its holdings in shares of KalVista Pharmaceuticals by 666.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company's stock valued at $54,000 after acquiring an additional 5,502 shares in the last quarter.

Insider Buying and Selling

In related news, CEO Benjamin L. Palleiko sold 32,979 shares of the stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $15.69, for a total transaction of $517,440.51. Following the sale, the chief executive officer owned 369,595 shares of the company's stock, valued at $5,798,945.55. This represents a 8.19% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Paul K. Audhya sold 2,776 shares of the stock in a transaction that occurred on Monday, May 19th. The stock was sold at an average price of $11.84, for a total value of $32,867.84. Following the sale, the insider directly owned 106,611 shares in the company, valued at $1,262,274.24. This represents a 2.54% decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 48,878 shares of company stock worth $723,617. 10.50% of the stock is owned by corporate insiders.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).